Evidencia disponible relativa a la eficacia de diferentes agentes endovesicales restituidores de glucosaminoglicanos empleados en cistitis intersticial

Arance, I.; Fata, F. Ramón de; Angulo, Javier C.; González-Enguita, C.; Errando, Carlos; Cózar, J.M.; Esteban, M.

doi:10.1016/j.acuro.2012.10.002

Cited by 4 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exogenous GAG therapy has been used for the treatment of chronic inflammatory bladder diseases for several years. 3,6,7 Even though it has been a widespread therapy worldwide, the available experience with the use of GAG is scarce, with few randomized clinical trials. Furthermore, studies focused primarily on BPS, while studies for recurrent UTIs and radiation cystitis are found in a smaller proportion.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, studies focused primarily on BPS, while studies for recurrent UTIs and radiation cystitis are found in a smaller proportion. 3 In BPS, some studies show significant improvement with treatment, although with a short follow-up (3-10 months). 2,8 Riedl et alt showed significant improvement in the VAS of 55% of the symptoms in BPS after treatment with intravesical GAG, in the same way in which Engelhart et al reported a decrease in symptoms from 81% to 27% in the immediate post-treatment., 27% at 6 months and 24% at 5 years after therapy.…”

Section: Discussionmentioning

confidence: 99%

“…The lack of these substances has been related to chronic lower urinary tract pathologies such as Bladder pain syndrome (BPS), recurrent urinary tract infection (recurrent UTIs) and radiation cystitis. [2][3][4] Therefore, the repair of the mucosa through the intravesical application of GAG has been proposed among the therapeutic options for these pathologies. 5 The purpose of this study is to describe the demographic characteristics of patients with BPS, radiation cystitis, and recurrent UTI in our population, as well as to evaluate the response to intravesical GAG treatment in these three clinical conditions.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Intravesical Glycosaminoglycans Experience for Chronic Lower Urinary Tract Pathology Treatment

Roa

Jaramillo²

2020

Revista Urología Colombiana / Colombian Urology Journal

View full text Add to dashboard Cite

Objective Intravesical glycosaminoglycans (GAG) treatment is one of the therapeutic options for chronic bladder pathologies and is approved for Bladder Pain Syndrome (BPS), radiation cystitis, and recurrent urinary tract infections (UTIs). The purpose of this study is to describe the demographic characteristics of patients with such pathologies in our population and to evaluate treatment response. Methods It is a retrospective study of patients with the aforementioned pathologies, who received treatment with GAG. Demographic characteristics and subjective improvement with treatment were evaluated. A bivariate analysis was performed to study possible improvement predictors. Results 53 patients were evaluated. Of them, 33 (62.3%) with BPS, 12 (22.6%) with recurrent UTIs, and 8 (15.1%) with radiation cystitis. The dose range received was between 4 - 20 instillations, with a median of 6 doses. 67.9% of patients showed improvement of symptoms with treatment, this percentage being even higher for the group of patients with recurrent UTIs (91%). No treatment response predictors were found. Conclusions Intravesical GAG treatment is a therapeutic alternative for patients with chronic bladder pathologies, with satisfactory results in the medium term. Prospective studies are needed to support the findings of this study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intravesical Glycosaminoglycans Experience for Chronic Lower Urinary Tract Pathology Treatment

Roa

Jaramillo²

2020

Revista Urología Colombiana / Colombian Urology Journal

View full text Add to dashboard Cite

show abstract

GAG replenishment therapy for bladder pain syndrome/interstitial cystitis

Wyndaele

Riedl²,

Taneja

et al. 2018

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims To present a rationale for the inclusion of urothelial coating dysfunction in the etipathogenesis of bladder pain syndrome/interstitial cystitis (BPS/IC) and the preclinical and clinical evidence in support of glycosaminoglycan (GAG) replenishment therapy in the treatment of BPS/IC, supplemented by the clinical experience of medical experts in the field and patient advocates attending a symposium on GAG replenishment at ESSIC’17, the annual Meeting of the International Society for the Study of Bladder Pain Syndrome, held in Budapest, Hungary in 2017. Results The urothelial GAG layer has a primary role in providing a permeability barrier to prevent penetration of urinary toxins and pathogens into the bladder wall. Disruption of the GAG layer contributes to the development of BPS/IC. The evidence shows that replenishment of GAGs can restore the GAG layer in BPS/IC, reducing inflammation, pain, and other symptoms. Conclusions Although data from large randomized controlled studies are limited, long clinical observation and the experience of clinicians and patients support the beneficial effects of intravesical GAG replenishment therapy for providing symptomatic relief for patients with BPS/IC.

show abstract

Interstitial cystitis/bladder pain syndrome

Wang¹

2014

Chronic Pelvic Pain

View full text Add to dashboard Cite

Evidencia disponible relativa a la eficacia de diferentes agentes endovesicales restituidores de glucosaminoglicanos empleados en cistitis intersticial

Cited by 4 publications

References 23 publications

Intravesical Glycosaminoglycans Experience for Chronic Lower Urinary Tract Pathology Treatment

Intravesical Glycosaminoglycans Experience for Chronic Lower Urinary Tract Pathology Treatment

GAG replenishment therapy for bladder pain syndrome/interstitial cystitis

Interstitial cystitis/bladder pain syndrome

Contact Info

Product

Resources

About